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Abstract
Irritable bowel syndrome (IBS) is a common gastro-
intestinal disorder that is generally considered to be 
functional because there appears to be no associated 
anatomical defect. Stress and psychological factors 
are thought to play an important role in IBS. The gut 
neuroendocrine system (NES), which regulates all func-
tions of the gastrointestinal tract, consists of endocrine 
cells that are scattered among the epithelial cells of the 
mucosa, and the enteric nervous system. Although it 
is capable of operating independently from the central 
nervous system (CNS), the gut NES is connected to 
and modulated by the CNS. This review presents evi-
dence for the presence of an anatomical defect in IBS 
patients, namely in the gastrointestinal endocrine cells. 
These cells have specialized microvilli that project into 
the lumen and function as sensors for the luminal con-
tent and respond to luminal stimuli by releasing hor-
mones into the lamina propria, which starts a chain re-
action that progresses throughout the entire NES. The 
changes in the gastrointestinal endocrine cells observed 
in IBS patients are highly consistent with the other ab-
normalities reported in IBS patients, such as visceral 
hypersensitivity, dysmotility, and abnormal secretion.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: This review presents recent observations in ir-
ritable bowel syndrome (IBS) patients that point toward 
the existence of an anatomical defect in the gastrointes-
tinal endocrine cells. It includes also an argument that 
IBS is an organic disorder and that the abnormalities in 
the gastrointestinal endocrine cells can explain the vis-
ceral hypersensitivity, dysmotility and abnormal secre-
tion reported in these patients.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a common chronic 
gastrointestinal disorder with a reported prevalence of  
5%-20% and an incidence of  about 200 per 100000 of  
the world population[1-29]. Patients with IBS suffer from 
recurrent abdominal pain/discomfort and altered bowel 
habit, which vary in both degree and time pattern be-
tween patients: from tolerable to severe, and from daily 
symptoms to intervals of  weeks/months, respective-
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ly[3,11,30-40]. IBS is more common in females than males, and 
in patients younger than 50 years of  age[3,11,14,15,19,21,26,30,31,33-40].
IBS is not associated with the development of  serious 
disease or with an excessive mortality rate[41,42]. However, 
it considerably reduces the sufferer’s quality of  life, inter-
fering with their education, working ability and social life. 
Moreover, IBS represents an economic burden to both 
patients and society[23,43-49], since IBS patients visit their 
doctors more frequently, undergo more diagnostic tests, 
consume more medications, miss more workdays, are less 
productive at work, and are hospitalized more frequently 
than those without IBS[28,32,39,50-53].
There are no biomarkers for the diagnosis of  IBS[54,55], 
which is instead based on the assessment of  symptoms 
such as the Rome Ⅲ criteria[56,57]. IBS patients are sub-
grouped according to differences in the predominant 
bowel symptoms as IBS-diarrhea (D), IBS-constipation 
(C), IBS-both diarrhea and constipation (M), and non-
subtyped IBS (patients with insufficient abnormality of  
stool consistency to meet the criteria for IBS-C, -D, or 
-M)[56,57]. The Rome criteria were introduced to facilitate 
positive diagnoses, reduce the costs due to unnecessary 
testing, and guide treatment; however, they fall short on 
these expectations and are generally neglected in clinical 
practice by both general practitioners and gastroenterolo-
gists[54,58-64].
IBS is considered to be a functional disorder in the 
absence of  a known anatomic defect[65], the pathophysiol-
ogy of  which is incompletely understood. The pathogen-
esis appears to be multifactorial, with several factors sug-
gested to play a role in the process, such as psychological 
factors, genetic factors, low-grade chronic intestinal 
inflammation, an abnormal gut neuroendocrine system 
(NES) and/or altered signaling in this system, dietary fac-
tors, and intestinal flora[66].
IBS patients can be roughly divided into two subsets: 
sporadic (nonspecific) and postinfectious (PI-IBS)/in-
flammatory bowel disease (IBD)-associated (IBD-IBS)[66]. 
Sporadic IBS includes patients who have had symptoms 
for a long time and without any associated events, in 
particular gastrointestinal or other infections. PI-IBS is 
defined as a sudden onset of  IBS symptoms following 
gastroenteritis in individuals who have previously had no 
gastrointestinal complaints, and IBD-IBS is defined in 
IBD patients in remission who display IBS symptoms[66]. 
PI-IBS constitutes about 6%-17% of  patients with IBS[67], 
and IBD-IBS occurs in 33%-46% of  ulcerative colitis pa-
tients and 42%-60% of  those with Crohn’s disease[68-72].
This article summarizes the published findings on 
abnormalities in the gut neuroendocrine cells, discusses 
them in view of  the currently known facts about IBS, 
and presents an argument for IBS being an organic gas-
trointestinal disorder.
GUT ENDOCRINE CELLS
The gut contains a large number of  endocrine cells that 
are dispersed among the epithelial cells of  the gut mucosa 
in all of  the gut segments except for the esophagus[66,73-78]. 
These cells constitute the largest endocrine organ in the 
body and comprise about 1% of  all epithelial cells in 
the gastrointestinal tract, where they are separated from 
one another by epithelial cells[73,74,79-81]. These cells have 
specialized microvilli that project into the lumen and 
function as sensors for the gut contents and respond to 
luminal stimuli by releasing hormones that, in general, 
target other parts of  the digestive system (Figure 1)[82-94]. 
There are at least 15 different populations of  endocrine 
cells in the gastrointestinal tract[60,73-76]. Some of  them 
[including somatostatin and peptide YY (PYY) cells] have 
long slender cytoplasmic processes that project toward 
neighboring cells, increasing their paracrine effects (Figure 
2)[95]. The distribution, functions, and modes of  action of  
the most important endocrine/paracrine cells are given in 
Table 1[60,75,76,96-108].
Some of  the different endocrine cell types are located 
in specific areas of  the gut, while others (primarily so-
matostatin and serotonin cells) are found throughout the 
gut[73,74,76]. They secrete one or more signaling substances 
into the lamina propria, where they exert their action lo-
cally on nearby structures (autocrine/paracrine mode) 
and/or via an endocrine mode of  action (by circulating in 
the blood to reach distant targets)[109]. These cells interact 
in an integrated manner with each other and with the 
enteric nervous system (ENS) and the afferent and effer-
ent nerve fibers of  the central nervous system (CNS), in 
particular the autonomic nervous system[60,76,99,110]. All of  
the cell types in the crypt/villus originate from pluripo-
385 January 14, 2014|Volume 20|Issue 2|WJG|www.wjgnet.com
El-Salhy M et al . Is IBS an organic disorder?
Lumen
Endocrine cell Epithelial cell
Submucosal ganglion
Afferent and efferent nerve fibers
Submucosa
Muscular layer
Myenteric ganglion
Figure 1  Schematic illustration of the gut neuroendocrine regulatory 
system. The endocrine cells are scattered among the epithelial cells and have 
specialized microvilli that project into the lumen and function as sensors of the 
gut contents, and they respond to luminal stimuli by releasing hormones into 
the lamina propria, where they exert their action locally on nearby structures. 
These endocrine cells interact with the enteric nervous system, which is in turn 
connected to and modulated by the central nervous system through afferent 
and efferent nerves.
tent stem cells of  endodermal origin[73,74,111]. Each intesti-
nal crypt contains four to six stem cells that differentiate 
into all epithelial cell types including enterocytes, goblet 
cells, Paneth cells, and endocrine cells[112-125]. These cells 
regulate several functions of  the gastrointestinal tract, 
including sensation, motility, secretion, absorption, local 
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  Cell content Localization Source of release Actions
  Serotonin 
  (5-HT) 
EC cells in the stomach, large and small 
intestines
Noradrenalin; acetylcholine; 
acidification and intraluminal 
pressure
Inhibits gastric emptying and stimulates colonic motility; 
accelerates small- and large-intestine transit activates the 
submucosal sensory branch of the enteric nervous system 
that conveys sensation from the gut to the central nervous 
system
  Histamine EC-like cells in the gastric oxyntic mucosa Vagus nerve stimulation and 
inhibited by somatostatin
Stimulates gastric acid secretion
  Somatostatin The stomach, and large and small 
intestines
Mixed meal and acidification of 
the stomach
Inhibits intestinal contraction; inhibits gut exocrine and 
neuroendocrine secretion
  Ghrelin Gastric oxyntic mucosa Protein and fat ingestion; 
suppressed by carbohydrate 
ingestion
Increases appetite and food intake; stimulates gastric and 
intestinal motility
  Gastrin Gastric antral mucosa Intraluminal peptides; amino 
acids; calcium; amines; low pH 
and prostaglandins. Somatostatin 
inhibits release
Stimulates gastric acid secretion and histamine release; 
trophic action on gastric mucosa; stimulates contraction of 
the LES and antrum
  CCK Small intestine, especially the duodenum Intraluminal protein and fat 
and inhibited by somatostatin
Inhibits gastric emptying; stimulates gallbladder contraction 
and intestinal motility; stimulates pancreatic exocrine 
secretion and growth; regulates food intake
  Secretin Small intestine, especially the duodenum Acidification and inhibited by 
somatostatin
Stimulates pancreatic bicarbonate and fluid secretion; 
inhibits gastric emptying; inhibits contractile activity of the 
small and large intestines
  GIP Small intestine, especially the duodenum Intraluminal glucose; amino 
acids and fat
Incretin action; inhibits gastric acid secretion
  Motilin Small intestine, especially the jejunum Protein and fat ingestion Induces phase-III migrating motor complex; stimulates 
gastric emptying; stimulates contraction of the LES
  Neurotensin Small intestine Fat Stimulates pancreatic section; inhibits gastric secretion; 
delays gastric emptying; stimulates colon motility
  PYY Terminal ileum and large intestine Protein-rich meals Delays gastric emptying; inhibits gastric and pancreatic 
secretion, stimulates the absorption of water and electrolytes; 
major mediator of the ileal brake
  PP Terminal ileum and large intestine Protein-rich meals Inhibits pancreatic secretion; stimulates gastric acid 
secretion; relaxes the gallbladder; stimulates motility of the 
stomach and small intestine
  Enteroglucagon
  (oxyntomodulin)
Terminal ileum and large intestine Intraluminal carbohydrates and 
fat
Inhibits gastric and pancreatic secretion; reduces gastric 
motility; has some incretin effect
  Chromogranin All gastrointestinal tract segments Ingestion of a meal Induces formation, sorting, and release of secretory granules 
of the gut endocrine/paracrine cells; an inflammatory 
mediator
Table 1  Overview of the main endocrine cells in the gastrointestinal tract
CCK: Cholecystokinin; EC: Enterochromaffin; GIP: Gastric inhibitory peptide; LES: Lower esophageal sphincter; PP: Pancreatic polypeptide; PYY: Peptide YY.
A B
Figure 2  The gut endocrine cells. A: A chromogranin-A-immunoreactive endocrine cell in the ileum. The endocrine cell extends from the basal membrane of the 
mucosa that project into the gut lumen; B: Somatostatin-immunoreactive cells in the gastric oxyntic mucosa. Note the long cytoplasmic processes (arrows), which can 
occasionally be seen to end at the base of parietal cells (arrowhead).
20 μm
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the stomach (Figure 3), proximal small intestine (duode-
num), distal small intestine (ileum), colon (Figure 4), and 
rectum of  patients with sporadic IBS[130-141]. These abnor-
malities manifest mostly as changes in the densities of  
these cells (i.e., an anatomical defect). The abnormalities 
in the different endocrine cells in the various segments of  
the gastrointestinal tract of  patients with sporadic IBS are 
summarized in Table 2. In addition to the abnormalities 
observed in the endocrine cells, there are alterations in 
the levels of  serotonin transporter (SERT), which appear 
to be increased in the ileum and decreased in the rectum 
of  IBS patients[130,141,142].
PI-IBS and IBD-IBS
Similar to sporadic IBS, abnormal endocrine/paracrine 
cell densities have been found in both PI-IBS and IBD-
IBS. However, the nature of  these abnormalities is differ-
ent from those in sporadic IBS (Table 3)[141,143-150].
POSSIBLE ROLE OF GASTROINTESTINAL 
ENDOCRINE CELL ABNORMALITIES IN IBS
The mechanisms regulated by gastrointestinal endocrine 
cells include gut sensation, motility, and secretion. IBS 
patients exhibit visceral hypersensitivity, disturbed gastro-
intestinal motility, and abnormal gut secretion[65,107,151-153]. 
The degree to which the abnormalities in these cells ob-
served in IBS patients contribute to these disturbed func-
tions is discussed to below.
Visceral hypersensitivity
Visceral hypersensitivity has been demonstrated in the 
colorectal segment of  IBS patients[154-161]. Hypersensitivity 
has also been reported in the esophagus, stomach, and 
small intestine[162-166]. However, visceral hypersensitivity 
is not present in all IBS patients, and a large prospec-
tive study found that only 20% of  IBS patients showed 
hypersensitivity[167]. Furthermore, visceral hypersensitiv-
ity does not seem to be a panintestinal disorder[165]; IBS 
patients only appear to exhibit rectal hypersensitivity[159]. 
Whether the severity of  abdominal pain is correlated 
with colorectal hypersensitivity in IBS remains a matter 
of  controversy[154,156,168-172].
As mentioned above, serotonin cells have special-
ized microvilli that project into the gut lumen and act 
as sensors for the gut contents, and in particular for in-
creased pressure. Serotonin is released in a regulated and 
calcium-dependent manner from serotonin cells into the 
surrounding tissues in response to luminal stimuli[173,174]. 
It activates the sensory branch of  the ENS, which is 
localized in the submucosal plexus in the submucosa, 
and the myenteric plexus in between the smooth muscle 
fibers. These sensory branches convey sensation from 
the gut to the CNS through the sympathetic and para-
sympathetic nervous systems (Figure 1)[175-177]. The pain 
stimuli activate the cerebral cortex through the thalamus 
and permit the recognition of  visceral pain[65,177]. Some 
studies have found IBS patients to be tolerant of  somatic 
immune defense, and food intake (by affecting the appe-
tite)[60,73,74,76,110].
ABNORMALITIES IN GUT ENDOCRINE 
CELLS IN IBS PATIENTS 
Several abnormalities have been reported in all segments 
of  the gastrointestinal tract of  patients with IBS. As 
mentioned above, the endocrine cells exert their effects 
in part locally; however for some of  them the endocrine 
mode of  action is difficult to elucidate[99]. One example 
of  this is the serotonin cells. The serotonin that they se-
crete is taken up into the blood and carried by platelets 
as they circulate through the gut[126-129]. Thus, the circu-
lating serotonin is locked within the dense granules of  
the platelets, without any possibility of  being delivered 
to distant targets. Therefore, summarizing and discuss-
ing abnormalities in the endocrine cells are considered 
separately herein relative to the various segments of  the 
gastrointestinal tract.
Sporadic IBS
Abnormal endocrine/paracrine cells have been found in 
  Gastrointestinal 
  segment
Endocrine cell type IBS-D IBS-M IBS-C
  Stomach
     Oxyntic mucosa Ghrelin High Normal Low
Serotonin High Normal Low
  Somatostatin Low Low High
Chromogranin A Normal Normal High
     Antrum Serotonin Normal Low High
Gastrin High High High
Somatostatin Low Low Low
Chromogranin A Normal Low High
  Small intestine
     Duodenum Serotonin Normal - Normal
CCK Low - Normal
Secretin Low - Normal
GIP Low - Low
Somatostatin Low - Low
  Chromogranin A Low - Low
     Ileum Serotonin Low Low Low
PYY Normal Normal High
Chromogranin A Low Low Low
  Large intestine
     Colon Serotonin Low - Low
PYY Low - Low
  Chromogranin A Low - Low
     Rectum Serotonin Normal - Normal
PYY Low - Low
Enteroglucagon Low - Low
Somatostatin High - High
Chromogranin A Normal - Normal
Table 2  Abnormalities in the densities of gastrointestinal 
endocrine/paracrine cells in patients with sporadic irritable 
bowel syndrome
CCK: Cholecystokinin; PYY: Peptide YY; GIP: Gastric inhibitory peptide; 
IBS-C: Irritable bowel syndrome (IBS) with constipation as the predomi-
nant bowel symptom; IBS-D: IBS with diarrhea as the predominant bowel 
symptom; IBS-M: IBS with both constipation and diarrhea as the predomi-
nant bowel symptoms.
El-Salhy M et al . Is IBS an organic disorder?
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pain, and hence the hypersensitivity is confined to the 
viscera[158,165,178], while other studies found IBS patients 
to have a lower tolerance to somatic pain than healthy 
subjects[162,179,180]. Azpiroz et al[167] postulated that the ex-
clusive visceral hypersensitivity experienced by some IBS 
patients could be attributable to abnormalities at the level 
of  the gut, spinal cord, or brain, whereas patients with 
both visceral and somatic hypersensitivities have a distur-
bance above the gut level. Those authors also argued that 
a peripheral mechanism is involved in the visceral hyper-
sensitivity in IBS.
The data presented in Table 2 suggest that none of  
the abnormalities in the gut endocrine cells could possibly 
contribute to the development of  the visceral hypersensi-
tivity seen in some sporadic IBS patients. However, it has 
been reported that SERT levels are increased in the ileum 
and reduced in the rectum of  these patients[130,141,142]. The 
gut mucosa has a high SERT-producing capacity, since 
all of  the epithelial cells lining the luminal surface of  the 
gut express SERT[142,181]. A reduction in SERT results in 
impaired intracellular uptake and degradation in the gut 
epithelial cells, consequently increasing the availability of  
serotonin within the gut mucosa[182,183]. Considering that 
the serotonin cell density in sporadic IBS does not differ 
from that of  a healthy subject, a decrease in SERT would 
markedly increase the amount of  serotonin available at 
its receptors[141,142]. An increase in serotonin at the 5-hy-
droxytryptamine (5-HT)3 receptors of  the ENS sensory 
neurons would activate the sensory nerves, which would 
then transmit nociceptive information to the nervous 
system[99]. Conversely, duodenal and rectal serotonin cell 
densities are high in PI-IBS patients, possibly contribut-
ing to the development of  visceral hypersensitivity.
Dysmotility
Dysmotility has been reported to occur in all segments of  
the gastrointestinal tract of  patients with IBS, but mostly 
in the small and large intestines[151,153]. Some studies found 
lower pressures in the lower esophageal sphincter and 
abnormal esophageal contractions in IBS patients[184,185]; 
however, such esophageal motility abnormalities were 
not confirmed in other studies[186,187]. In addition, some 
authors have reported abnormal gastric emptying in 
patients with IBS[153,188-193], while others did not find any 
such abnormality in these patients[161,194-197]. It therefore 
seems that abnormalities of  gastric emptying do not oc-
cur in all IBS patients. Furthermore, while IBS-C patients 
often exhibit delayed gastric emptying, rapid gastric emp-
tying is found in IBS-D patients[153,189].
The ghrelin cell density in the gastric oxyntic mucosa 
is low and the serotonin cell density in the antrum of  the 
stomach is high in IBS-C patients, while in IBS-D pa-
tients the ghrelin cell density in the gastric oxyntic muco-
sa is high and the densities of  cholecystokinin (CCK) and 
secretin cells are reduced in the duodenum[132]. Ghrelin is 
a peptide hormone that was first isolated from the stom-
ach, and originates mostly from endocrine cells in the 
oxyntic mucosa of  the stomach, although small amounts 
are expressed in the small intestine, large intestine, and 
the arcuate nucleus of  the hypothalamus[198-200]. Ghrelin 
has several functions, and plays a role in regulating the re-
lease of  growth hormone from the pituitary gland, which 
increases appetite and feeding, and also plays a major role 
in energy metabolism[201-204]. Furthermore, ghrelin has 
been found to accelerate gastric and small- and large-in-
testine motility[83,110,205-214]. Serotonin acts on 5-HT1p recep-
tors, which are located on a subset of  inhibitory motor 
neurons of  the myenteric plexus, relaxing the stomach via 
Figure 3  Ghrelin-immunoreactive cells. A: Ghrelin-immunoreactive cells in the gastric oxyntic mucosa of a healthy subject; B: In a patient with irritable bowel syn-
drome (IBS) with diarrhea as the predominant bowel symptom (IBS-D); C: In a patient with IBS with constipation as the predominant bowel symptom (IBS-C). The 
density of ghrelin cells is higher in IBS-D and lower in IBS-C than in the healthy control.
  Gastrointestinal   
  segment
Endocrine cell type PI-IBS IBD-IBS
  Small intestine
     Duodenum Serotonin High -
CCK High -
  Large intestine
  Serotonin High High/low
PYY High Low
PP - Low
Enteroglucagon - High
Table 3  Abnormalities in the densities of gastrointestinal 
endocrine/paracrine cells in patients with post infectious 
irritable bowel syndrome and inflammatory-bowel-disease-
associated irritable bowel syndrome 
CCK: Cholecystokinin; PYY: Peptide YY; PI-IBS: Post infectious irritable 
bowel syndrome; IBD-IBS: Inflammatory-bowel-disease-associated irri-
table bowel syndrome.
A B C
20 μm 20 μm 20 μm
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a nitrergic pathway and delaying gastric emptying[98,215-217]. 
CCK relaxes the proximal stomach in order to increase its 
reservoir capacity, and inhibits gastric emptying[218-220]. Se-
cretin also inhibits gastric emptying[76,221]. It is therefore 
conceivable that low gastric ghrelin and high serotonin 
contribute to the slow gastric emptying in IBS-C, while 
the high gastric ghrelin and low intestinal CCK and secre-
tin contribute to the rapid gastric emptying in IBS-D.
Several studies have found small-bowel transit to be 
delayed in IBS-C and accelerated in IBS-D[195,222-226]. How-
ever, a study from the Mayo clinic found no overall as-
sociation between these IBS subgroups[161]. Studies on the 
motor patterns of  the small bowel in IBS yielded con-
tradictory results, which is probably due to marked inter- 
and intraindividual variations of  small-intestine motor 
patterns[194,227-243]. As mentioned above, ghrelin cell density 
is low in the gastric oxyntic mucosa and PYY cell den-
sity is high in the ileum of  IBS-C patients. Since ghrelin 
stimulates small-intestine motility and PYY stimulates the 
absorption of  water and electrolytes, and is a major regu-
lator of  the ileal brake[244-249]. Moreover, it inhibits prosta-
glandin E2 and vasoactive intestinal polypeptide (which 
stimulate intestinal fluid secretion)[250-252], it is possible that 
the abnormalities in gastric ghrelin and ileal PYY contrib-
ute to the slow small-intestine transit in IBS-C. Secretin 
inhibits the contractile activity of  the small intestine, and 
so the high ghrelin cell density and low duodenal secretin 
cell density may play a role in the rapid small-intestine 
transit in IBS-D.
It has been reported by some that colorectal transit is 
delayed in IBS-C and accelerated in IBS-D[153,222,223,253-258]. 
However, others have found that the colorectal transit 
time does not differ between IBS patients and con-
trols[225,253,254]. The myoelectric and motor patterns of  the 
large intestine of  IBS patients have been investigated 
by several studies, which have yielded contradictory re-
sults[196,254-279]. In IBS-C, ghrelin cell density in the gastric 
oxyntic mucosa is low and ileal PYY cell density is high. 
Given that ghrelin stimulates intestinal motility and PYY 
stimulates the ileal-break, these abnormalities in ghrelin 
and PYY may promote the delayed colorectal transit ob-
served in some IBS-C patients. CCK and secretin inhibit 
intestinal motility, and the cell densities of  both are low in 
the duodenum of  IBS-D patients. These factors together 
with a high gastric ghrelin cell density may contribute to 
the development of  the accelerated colorectal transit seen 
in IBS-D patients.
In PI-IBS, the serotonin cell densities are high both 
in the small and large intestines, and CCK cell density 
is high in the small intestine. Serotonin primarily targets 
the mucosal projections of  the intrinsic primary affer-
ent neurons, which initiate peristaltic and secretory re-
flexes[156-161,175,280-289]. As mentioned above, CCK stimulates 
intestinal motility; thus, high serotonin and CCK levels 
could be responsible for the diarrhea seen in PI-IBS.
Abnormal secretion
Few studies have investigated gastrointestinal secretion in 
IBS patients. Enhanced intestinal secretion in response 
to bile acid perfusion in the ileum has been reported in 
these patients[290]. Increased reactivity of  the secretory 
component of  the migrating motor complex has been 
observed in the small intestine of  IBS patients, and espe-
cially in those with IBS-D[291]. Among the abnormalities 
in the gut endocrine cells in IBS patients listed in Table 2, 
the low duodenal CCK and secretin observed in IBS-D, 
and the high ileal PYY cell density observed in IBS-C 
are particularly interesting with respect to gut secre-
tions. CCK stimulates the secretion of  digestive enzymes 
from pancreatic exocrine glands, and secretin stimulates 
pancreatic bicarbonate and fluid secretions[218,219]. The 
secretion of  pancreatic bicarbonate increases the pH of  
the gut contents, which are highly acidic after leaving the 
stomach, and PYY stimulates the absorption of  water 
and electrolytes[76]. This change in pH is essential for 
lipid digestion, since pancreatic lipase is irreversibly inac-
tivated below pH 4.0[218]. It is tempting to speculate that 
IBS-D patients could suffer from fat maldigestion and a 
functional pancreatic insufficiency. Indeed, pancreatic en-
zyme substitution and a low-fat diet have been applied in 
clinical practice for these patients, with some success[292]. 
Moreover, an increase in PYY in the ileum of  IBS-C pa-
tients may result in increased absorption of  water from 
the feces, resulting in hard feces that worsen their to ob-
stipation (Figure 4).
In conclusion, there are sufficient grounds to suspect 
Figure 4  Peptide YY-immunoreactive cells. A: In the colon of a healthy subject; B: In a patient with irritable bowel syndrome (IBS). The density of peptide YY cells 
in the colon is lower in IBS patients than in healthy controls.
A B
100 μm 100 μm
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that the abnormalities in the gastrointestinal endocrine 
cells play a role in the development of  visceral hypersen-
sitivity, gastrointestinal dysmotility, and abnormal gastro-
intestinal secretion.
IS IBS AN ORGANIC DISORDER?
It has long been considered that IBS is caused by psy-
chological stress and/or brain dysfunction, and it is 
overrepresented in patients with psychiatric illness/and 
or sexually and/or physically abused individuals. During 
the past decade there has been rapid progress in our un-
derstanding of  IBS, and there is accumulating evidence 
of  a biological etiology for this condition. Research to 
establish effective treatments for IBS have been intensi-
fied, and societal attitudes toward IBS patients are slowly 
changing.
This review presents evidence for an anatomic defect 
in IBS patients, namely the gastrointestinal endocrine 
cells. However, the data presented on the gastrointestinal 
endocrine cells in sporadic IBS were obtained by only 
two research groups. Further studies performed by other 
researchers involving different patient cohorts are needed 
before these observations can be confirmed. Conversely, 
while the data for PI-IBS were reported by several re-
search groups from different countries and related to 
different patient cohorts, studies on PI-IBS have focused 
mainly on serotonin and are mostly restricted to the 
rectum. Further studies of  other endocrine cells in dif-
ferent segments of  the gastrointestinal tract are needed 
in PI-IBS. It should be noted that the gastrointestinal 
endocrine cells interact in an integrated manner with each 
other and the ENS, and together constitute the so-called 
neuroendocrine regulatory system of  the gut[76,293-295]. It 
is thus possible that IBS patients have an abnormality 
in the ENS, in addition to those in the endocrine cells. 
However, investigating the ENS is very difficult since it 
would require whole-wall biopsy sampling under laparo-
scopic control, which represents a risk for both patients 
and controls. Regardless of  the ethical issues this raises, 
it is unlikely that either patients or healthy subjects would 
voluntarily submit to laparoscopy and whole-wall biopsy 
sampling.
The abnormalities in the gut endocrine cells differ be-
tween sporadic IBS and PI-IBS/IBD-IBS, and their eti-
ologies also appear to be different. Familial aggregation, 
twin, and genetic studies provide evidence for a genetic 
predisposition in sporadic IBS[296-306], and these patients 
describe their symptoms as commencing in childhood, 
suggesting the presence of  genetically defective gastro-
intestinal endocrine cells. However, gastrointestinal mu-
cosal cells - including the endocrine cells - have a rapid 
turnover, and it is also possible that factors related to lu-
minal content such as diet or bacterial flora can provoke 
an increase or decrease in the endocrine cell population.
The etiology of  the gastrointestinal endocrine cell 
abnormalities in PI-IBS and IBD-IBS appears to dif-
fer from that of  sporadic IBS. Patients who develop PI-
IBS and IBD-IBS likely have a genetic predisposition 
(host related) as well as other factors, such as infecting-
organism-associated risk factors[307-315]. Following infec-
tion, these patients develop a low-grade inflammation 
that manifests as an increased intraepithelial and mucosal 
infiltration of  lymphocytes and mast cells[143-149,316]. There 
is some evidence that inflammation and immune cells 
affect the gastrointestinal endocrine cells[317]. The secre-
tion of  serotonin by enterochromaffin (EC) cells can be 
enhanced or attenuated by the secretory products of  im-
mune cells, such as CD4+ T, and also modulates the im-
mune response[126,317]. The EC cells are in contact with or 
very close to CD3+ and CD20+ lymphocytes, and several 
serotonergic receptors have been identified in lympho-
cytes, monocytes, macrophages, and dendritic cells[318]. 
Therefore, it is conceivable that the abnormalities in the 
gastrointestinal endocrine cells in PI-IBS and IBD-IBS 
are caused by endocrine/immune interactions (i.e., the 
endocrine/immune axis), which are in turn caused by 
low-grade inflammation in predisposed individuals[319,320].
CONCLUSION
The gut NES comprises the gastrointestinal endocrine 
cells and the ENS[76]. This regulatory system controls 
all gastrointestinal functions independently from the 
CNS[76,156]. However, the gut NES and the CNS are con-
nected, and the CNS modulates the gastrointestinal func-
tions through this connection[152]. Thus, a defect in the 
gut NES should be suspected in patients with IBS[76,294]. 
The gastrointestinal endocrine cells serve as chemical and 
mechanical transducers for afferent projections to the 
ENS, and subsequently to the CNS[294,321]. The present 
review describes evidence in the literature of  an anatomic 
defect in the NES in IBS, namely defective gastrointes-
tinal endocrine cells. Therefore, in line with some other 
gastroenterologists, we consider it highly likely that IBS is 
an organic disorder[107]. 
The endocrine cells interact in an integrated man-
ner with each other. It is possible that the abnormality 
in many endocrine cells of  the gut seen in IBS is caused 
by a defect in one or more endocrine cell types, which in 
turn results in changes in the other endocrine cell types.
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